Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of -91.00% is 6189% below its 5-year average of 1.49%, near the high end of its 5-year range (-1629.41%–100.00%).
1027.12% below its 12-month average of 9.82%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
GROSS MARGIN
-91.00%
GROSS MARGIN AVG TTM
9.82%
GROSS MARGIN AVG 3Y
0.00%
GROSS MARGIN AVG 5Y
1.49%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-1027.12%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
-6189.19%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
46.51%
median of 525 covered companies
CURRENT VS SECTOR MEDIAN
-295.66%
vs the sector median at left
Inhibrx Biosciences Inc.
Market Cap
$1.40B
Gross Margin
-91.00%
TTM Avg
9.82%
3Y Avg
0.00%
5Y Avg
1.49%
Market Cap
$1.40B
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$1.38B
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$1.43B
Gross Margin
98.97%
TTM Avg
9.74%
3Y Avg
-353.69%
5Y Avg
-246.22%
Market Cap
$1.47B
Gross Margin
17.33%
TTM Avg
13.16%
3Y Avg
12.65%
5Y Avg
13.31%
Market Cap
$1.33B
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Inhibrx Biosciences Inc. (INBX) | $1.40B | -91.00% | 9.82% | 0.00% | 1.49% |
| Kailera Therapeutics, Inc. (KLRA)vs › | $1.40B | 0.00% | 0.00% | 0.00% | 0.00% |
| Hemab Therapeutics Holdings, Inc. Common Stock (COAG)vs › | $1.38B | 0.00% | 0.00% | 0.00% | 0.00% |
| AnaptysBio, Inc. (ANAB)vs › | $1.43B | 98.97% | 9.74% | -353.69% | -246.22% |
| Alpha Tau Medical Ltd (DRTS)vs › | $1.36B | 0.00% | 0.00% | 0.00% | 0.00% |
| Healthcare Services Group, Inc. (HCSG)vs › | $1.47B | 17.33% | 13.16% | 12.65% | 13.31% |
| Braveheart Bio, Inc. (BRVE)vs › | $1.45B | N/A | N/A | N/A | N/A |
| ArriVent BioPharma, Inc. (AVBP)vs › | $1.33B | 0.00% | 0.00% | 0.00% | 0.00% |
| GH Research PLC (GHRS)vs › | $1.51B | 0.00% | 0.00% | 0.00% | 0.00% |
| Kardigan, Inc. (KARD)vs › | $1.29B | 0.00% | 0.00% | 0.00% | 0.00% |
Gross Margin
-91.0%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 49.08% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | -589.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 100.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 81.76% |
| 2023-09-30 | -155.46% |
| 2023-06-30 | -883.33% |
| 2023-03-31 | -1629.41% |
| 2022-12-31 | -162.77% |
| 2022-09-30 | -158.63% |
| 2022-06-30 | 0.42% |
| 2022-03-31 | 23.61% |
| 2021-12-31 | 75.60% |
| 2021-09-30 | 73.30% |
| 2021-06-30 | 100.00% |
| 2021-03-31 | -1804.75% |
| 2020-12-31 | 100.00% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | 100.00% |
| 2019-12-31 | 98.50% |
| 2019-09-30 | 36.27% |
| 2019-06-30 | 110.50% |
| 2019-03-31 | 122.95% |
| 2018-12-31 | -106.26% |
| 2018-06-30 | -239.80% |
| 2018-03-31 | -331.16% |
| 2017-12-31 | -2493.95% |
